최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Biomolecules & therapeutics, v.30 no.4, 2022년, pp.299 - 308
Lee, Hyang-Mi (College of Pharmacy, Dongduk Women's University)
T cells are attractive targets for the development of immunotherapy to treat cancer due to their biological features, capacity of cytotoxicity, and antigen-specific binding of receptors. Novel strategies that can modulate T cell functions or receptor reactivity provide effective therapies, including...
Ansell S. M. Lesokhin A. M. Borrello I. Halwani A. Scott E. C. Gutierrez M. Schuster S. J. Millenson M. M. Cattry D. Freeman G. J. Rodig S. J. Chapuy B. Ligon A. H. Zhu L. Grosso J. F. Kim S. Y. Timmerman J. M. Shipp M. A. Armand P. 2015 PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N. Engl. J. Med. 372 311 319 10.1056/NEJMoa1411087 25482239
Aung P. P. Liu Y. C. Ballester L. Y. Robbins P. F. Rosenberg S. A. Lee C. C. 2014 Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma Hum. Pathol. 45 259 267 10.1016/j.humpath.2013.05.029 24290058
Bendell J. C. Fong L. Stein M. N. Beer T. M. Ross A. Gao X. Weitzman A. Austin R. Ganti V. Law C. Lemon B. Wesche H. De Bono J. S. 2020 First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC) J. Clin. Oncol. 38 5552 10.1200/JCO.2020.38.15_suppl.5552
Bielamowicz K. Fousek K. Byrd T. T. Samaha H. Mukherjee M. Aware N. Wu M. F. Orange J. S. Sumazin P. Man T. K. Joseph S. K. Hegde M. Ahmed N. 2018 Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma Neuro-Oncol. 20 506 518 10.1093/neuonc/nox182 29016929
Brentjens R. J. Davila M. L. Riviere I. Park J. Wang X. Cowell L. G. Bartido S. Stefanski J. Taylor C. Olszewska M. Borquez-Ojeda O. Qu J. Wasielewska T. He Q. Bernal Y. Rijo I. V. Hedvat C. Kobos R. Curran K. Steinherz P. Jurcic J. Rosenblat T. Maslak P. Frattini M. Sadelain M. 2013 CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci. Transl. Med. 5 177ra38 10.1126/scitranslmed.3005930 23515080
Brocker T. 2000 Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells Blood 96 1999 2001 10.1182/blood.V96.5.1999 10961908
Brudno J. N. Kochenderfer J. N. 2016 Toxicities of chimeric antigen receptor T cells: recognition and management Blood 127 3321 3330 10.1182/blood-2016-04-703751 27207799
Campbell C. E. Kuriyan N. P. Rackley R. R. Caulfield M. J. Tubbs R. Finke J. Williams B. R. 1998 Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma Int. J. Cancer 78 182 188 10.1002/(SICI)1097-0215(19981005)78:2<182::AID-IJC11>3.0.CO;2-D 9754650
Carpenter R. O. Evbuomwan M. O. Pittaluga S. Rose J. J. Raffeld M. Yang S. Gress R. E. Hakim F. T. Kochenderfer J. N. 2013 B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma Clin. Cancer Res. 19 2048 2060 10.1158/1078-0432.CCR-12-2422 23344265
Carreno B. M. Collins M. 2002 The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses Annu. Rev. Immunol. 20 29 53 10.1146/annurev.immunol.20.091101.091806 11861596
Chandran S. S. Klebanoff C. A. 2019 T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance Immunol. Rev. 290 127 147 10.1111/imr.12772 31355495
Chen D. S. Mellman I. 2013 Oncology meets immunology: the cancer-immunity cycle Immunity 39 1 10 10.1016/j.immuni.2013.07.012 23890059
Chen R. Zinzani P. L. Lee H. J. Armand P. Johnson N. A. Brice P. Radford J. Ribrag V. Molin D. Vassilakopoulos T. P. Tomita A. von Tresckow B. Shipp M. A. Lin J. Kim E. Nahar A. Balakumaran A. Moskowitz C. H. 2019 Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 Blood 134 1144 1153 10.1182/blood.2019000324 31409671
Chow M. T. Möller A. Smyth M. J. 2012 Inflammation and immune surveillance in cancer Semin. Cancer Biol. 22 23 32 10.1016/j.semcancer.2011.12.004 22210181
Cohen E. E. W. Soulieres D. Le Tourneau C. Dinis J. Licitra L. Ahn M. J. Soria A. Machiels J. P. Mach N. Mehra R. Burtness B. Zhang P. Cheng J. Swaby R. F. Harrington K. J. KEYNOTE-040 investigators 2019 Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Lancet 393 156 167 10.1016/S0140-6736(18)31999-8 30509740
Correnti C. E. Laszlo G. S. de van der Schueren W. Godwin C. D. Bandaranayake A. Busch M. A. Gudgeon C. J. Bates O. M. Olson J. M. Mehlin C. Walter R. B. 2018 Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation Leukemia 32 1239 1243 10.1038/s41375-018-0014-3 29588544
Costa L. J. Wong S. W. Bermúdez A. de la Rubia J. Mateos M. Ocio E. M. Rodríguez-Otero P. San-Miguel J. Li S. Sarmiento R. Lardelli P. Gaudy A. Boss I. Kelly L. M. Burgess M. R. Hege K. Bensinger W. I. 2019 First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial Blood 134 Supplement_1 143 10.1182/blood-2019-122895
D'Angelo S. P. Melchiori L. Merchant M. S. Bernstein D. Glod J. Kaplan R. Grupp S. Tap W. D. Chagin K. Binder G. K. Basu S. Lowther D. E. Wang R. Bath N. Tipping A. Betts G. Ramachandran I. Navenot J. M. Zhang H. Wells D. K. Van Winkle E. Kari G. Trivedi T. Holdich T. Pandite L. Amado R. Mackall C. L. 2018 Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259) T cells in synovial sarcoma Cancer Discov. 8 944 957 10.1158/2159-8290.CD-17-1417 29891538
Daver N. Alotaibi A. S. Bücklein V. Subklewe M. 2021 T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments Leukemia 35 1843 1863 10.1038/s41375-021-01253-x 33953290
Decker W. K. Safdar A. 2009 Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited Cytokine Growth Factor Rev. 20 271 281 10.1016/j.cytogfr.2009.07.004 19656718
D'Ippolito E. Schober K. Nauerth M. Busch D. H. 2019 T cell engineering for adoptive T cell therapy: safety and receptor avidity Cancer Immunol. Immunother. 68 1701 1712 10.1007/s00262-019-02395-9 31542797
Fecci P. E. Ochiai H. Mitchell D. A. Grossi P. M. Sweeney A. E. Archer G. E. Cummings T. Allison J. P. Bigner D. D. Sampson J. H. 2007 Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function Clin. Cancer Res. 13 2158 2167 10.1158/1078-0432.CCR-06-2070 17404100
Ferris R. L. Blumenschein G. Fayette J. Guigay J. Colevas A. D. Licitra L. Harrington K. Kasper S. Vokes E. E. Even C. Worden F. Saba N. F. Iglesias Docampo L. C. Haddad R. Rordorf T. Kiyota N. Tahara M. Monga M. Lynch M. Geese W. J. Kopit J. Shaw J. W. Gillison M. L. 2016 Nivolumab for recurrent squamous-cell carcinoma of the head and neck N. Engl. J. Med. 375 1856 1867 10.1056/NEJMoa1602252 27718784
Garrido F. Aptsiauri N. Doorduijn E. M. Garcia Lora A. M. van Hall T. 2016 The urgent need to recover MHC class I in cancers for effective immunotherapy Curr. Opin. Immunol. 39 44 51 10.1016/j.coi.2015.12.007 26796069
Ghorashian S. Kramer A. M. Onuoha S. Wright G. Bartram J. Richardson R. Albon S. J. Casanovas-Company J. Castro F. Popova B. Villanueva K. Yeung J. Vetharoy W. Guvenel A. Wawrzyniecka P. A. Mekkaoui L. Cheung G. W. Pinner D. Chu J. Lucchini G. Silva J. Ciocarlie O. Lazareva A. Inglott S. Gilmour K. C. Ahsan G. Ferrari M. Manzoor S. Champion K. Brooks T. Lopes A. Hackshaw A. Farzaneh F. Chiesa R. Rao K. Bonney D. Samarasinghe S. Goulden N. Vora A. Veys P. Hough R. Wynn R. Pule M. A. Amrolia P. J. 2019 Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR Nat. Med. 25 1408 1414 10.1038/s41591-019-0549-5 31477906
Gilboa E. 1999 The makings of a tumor rejection antigen Immunity 11 263 270 10.1016/S1074-7613(00)80101-6 10514004
Gong J. Chehrazi-Raffle A. Reddi S. Salgia R. 2018 Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations J. Immunother. Cancer 6 8 10.1186/s40425-018-0316-z 29357948
Grosso J. F. Jure-Kunkel M. N. 2013 CTLA-4 blockade in tumor models: an overview of preclinical and translational research Cancer Immun. 13 5 23390376
Grupp S. A. Kalos M. Barrett D. Aplenc R. Porter D. L. Rheingold S. R. Teachey D. T. Chew A. Hauck B. Wright J. F. Milone M. C. Levine B. L. June C. H. 2013 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med. 368 1509 1518 10.1056/NEJMoa1215134 23527958
Halliday G. M. Patel A. Hunt M. J. Tefany F. J. Barnetson R. S. 1995 Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells World J. Surg. 19 352 358 10.1007/BF00299157 7638987
Hargadon K. M. Johnson C. E. Williams C. J. 2018 Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors Int. Immunopharmacol. 62 29 39 10.1016/j.intimp.2018.06.001 29990692
Harrison S. J. Minnema M. C. Lee H. C. Spencer A. Kapoor P. Madduri D. Larsen J. Ailawadhi S. Kaufman J. L. Raab M. S. Hari P. Iida S. Vij R. Davies F. E. Lesley R. Upreti V. V. Yang Z. Sharma A. Minella A. Lentzsch S. 2020 A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM) Blood 136 28 29 10.1182/blood-2020-134063
Herbst R. S. Baas P. Kim D. W. Felip E. Perez-Gracia J. L. Han J. Y. Molina J. Kim J. H. Arvis C. D. Ahn M. J. Majem M. Fidler M. J. de Castro G. Garrido M. Lubiniecki G. M. Shentu Y. Im E. Dolled-Filhart M. Garon E. B. 2016 Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 387 1540 1550 10.1016/S0140-6736(15)01281-7 26712084
Hilal T. Prasad V. 2018 Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission Nat. Rev. Clin. Oncol. 15 727 728 10.1038/s41571-018-0087-y 30181661
Hirano F. Kaneko K. Tamura H. Dong H. Wang S. Ichikawa M. Rietz C. Flies D. B. Lau J. S. Zhu G. Tamada K. Chen L. 2005 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res. 65 1089 1096 10.1158/0008-5472.1089.65.3 15705911
Hodi F. S. Mihm M. C. Soiffer R. J. Haluska F. G. Butler M. Seiden M. V. Davis T. Henry-Spires R. MacRae S. Willman A. Padera R. Jaklitsch M. T. Shankar S. Chen T. C. Korman A. Allison J. P. Dranoff G. 2003 Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc. Natl. Acad. Sci. U.S.A. 100 4712 4717 10.1073/pnas.0830997100 12682289
Hodi F. S. O'Day S. J. McDermott D. F. Weber R. W. Sosman J. A. Haanen J. B. Gonzalez R. Robert C. Schadendorf D. Hassel J. C. Akerley W. van den Eertwegh A. J. Lutzky J. Lorigan P. Vaubel J. M. Linette G. P. Hogg D. Ottensmeier C. H. Lebbe C. Peschel C. Quirt I. Clark J. I. Wolchok J. D. Weber J. S. Tian J. Yellin M. J. Nichol G. M. Hoos A. Urba W. J. 2010 Improved survival with ipilimumab in patients with metastatic melanoma. N . Engl . J . Me d. 363 711 723 10.1056/NEJMoa1003466 20525992
Hoffmann M. M. Slansky J. E. 2020 T-cell receptor affinity in the age of cancer immunotherapy Mol. Carcinog. 59 862 870 10.1002/mc.23212 32386086
Huang J. Brameshuber M. Zeng X. Xie J. Li Q. J. Chien Y. H. Valitutti S. Davis M. M. 2013 A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells Immunity 39 846 857 10.1016/j.immuni.2013.08.036 24120362
Huang L. Q. Brasseur F. Serrano A. De Plaen E. van der Bruggen P. Boon T. Van Pel A. 1999 Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma J. Immunol. 162 6849 6854 10352307
Hummel H. D. Kufer P. Grüllich C. Seggewiss-Bernhardt R. Deschler-Baier B. Chatterjee M. Goebeler M. E. Miller K. de Santis M. Loidl W. Dittrich C. Buck A. Lapa C. Thurner A. Wittemer-Rump S. Koca G. Boix O. Döcke W. D. Finnern R. Kusi H. Ajavon-Hartmann A. Stienen S. Sayehli C. M. Polat B. Bargou R. C. 2021 Pasotuxizumab, a BiTE(®) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings Immunotherapy 13 125 141 10.2217/imt-2020-0256 33172323
Hung C. F. Xu X. Li L. Ma Y. Jin Q. Viley A. Allen C. Natarajan P. Shivakumar R. Peshwa M. V. Emens L. A. 2018 Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA-transfected peripheral blood lymphocytes for ovarian cancer therapy Hum. Gene Ther. 29 614 625 10.1089/hum.2017.080 29334771
Imai C. Mihara K. Andreansky M. Nicholson I. C. Pui C. H. Geiger T. L. Campana D. 2004 Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 18 676 684 10.1038/sj.leu.2403302 14961035
Ishiguro T. Sano Y. Komatsu S. I. Kamata-Sakurai M. Kaneko A. Kinoshita Y. Shiraiwa H. Azuma Y. Tsunenari T. Kayukawa Y. Sonobe Y. Ono N. Sakata K. Fujii T. Miyazaki Y. Noguchi M. Endo M. Harada A. Frings W. Fujii E. Nanba E. Narita A. Sakamoto A. Wakabayashi T. Konishi H. Segawa H. Igawa T. Tsushima T. Mutoh H. Nishito Y. Takahashi M. Stewart L. ElGabry E. Kawabe Y. Ishigai M. Chiba S. Aoki M. Hattori K. Nezu J. 2017 An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors Sci. Transl. Med. 9 eaal4291 10.1126/scitranslmed.aal4291 28978751
Iwai Y. Ishida M. Tanaka Y. Okazaki T. Honjo T. Minato N. 2002 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc. Natl. Acad. Sci. U.S.A. 99 12293 12297 10.1073/pnas.192461099 12218188
Karapetyan A. R. Chaipan C. Winkelbach K. Wimberger S. Jeong J. S. Joshi B. Stein R. B. Underwood D. Castle J. C. van Dijk M. Seibert V. 2019 TCR fingerprinting and off-target peptide identification Front. Immunol. 10 2501 10.3389/fimmu.2019.02501 31695703
Klinger M. Benjamin J. Kischel R. Stienen S. Zugmaier G. 2016 Harnessing T cells to fight cancer with BiTE(R) antibody constructs--past developments and future directions Immunol. Rev. 270 193 208 10.1111/imr.12393 26864113
Klinger M. Zugmaier G. Nagele V. Goebeler M. E. Brandl C. Stelljes M. Lassmann H. von Stackelberg A. Bargou R. C. Kufer P. 2020 Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events Cancer Res. 80 91 101 10.1158/0008-5472.CAN-19-1131 31662326
Kontermann R. E. Brinkmann U. 2015 Bispecific antibodies Drug Discov. Today 20 838 847 10.1016/j.drudis.2015.02.008 25728220
Kumar V. Chaudhary N. Garg M. Floudas C. S. Soni P. Chandra A. B. 2017 Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy Front. Pharmacol. 8 49 10.3389/fphar.2017.00049 28228726
Kuwana Y. Asakura Y. Utsunomiya N. Nakanishi M. Arata Y. Itoh S. Nagase F. Kurosawa Y. 1987 Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions Biochem. Biophys. Res. Commun. 149 960 968 10.1016/0006-291X(87)90502-X 3122749
Leach D. R. Krummel M. F. Allison J. P. 1996 Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1734 1736 10.1126/science.271.5256.1734 8596936
Lee L. Wang R. F. Wang X. Mixon A. Johnson B. E. Rosenberg S. A. Schrump D. S. 1999 NY-ESO-1 may be a potential target for lung cancer immunotherapy Cancer J. Sci. Am. 5 20 25 10188057
Liu Y. Zheng P. 2020 Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy Trends Pharmacol. Sci. 41 4 12 10.1016/j.tips.2019.11.003 31836191
Loffler A. Kufer P. Lutterbuse R. Zettl F. Daniel P. T. Schwenkenbecher J. M. Riethmuller G. Dorken B. Bargou R. C. 2000 A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 95 2098 2103 10.1182/blood.V95.6.2098 10706880
Lorenczewski G. Friedrich M. Kischel R. Dahlhoff C. Anlahr J. Balazs M. Rock D. Boyle M. C. Goldstein R. Coxon A. Chapman-Arvedson T. 2017 Generation of a half-life extended anti-CD19 BiTE® antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies Blood 130 2815
Lu Y. Parker L. Lu T. Zheng Z. Yao X. Robbins P. F. van der Bruggen P. Klebanoff C. A. Hinrichs C. S. Goff S. Sherry R. Kammula U. Yang J. C. Rosenberg S. A. 2015 A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers. J. Immunother Cancer 3 P158 10.1186/2051-1426-3-S2-P158
Lynn R. C. Weber E. W. Sotillo E. Gennert D. Xu P. Good Z. Anbunathan H. Lattin J. Jones R. Tieu V. Nagaraja S. Granja J. de Bourcy C. F. A. Majzner R. Satpathy A. T. Quake S. R. Monje M. Chang H. Y. Mackall C. L. 2019 c-Jun overexpression in CAR T cells induces exhaustion resistance Nature 576 293 300 10.1038/s41586-019-1805-z 31802004
Maher J. Brentjens R. J. Gunset G. Riviere I. Sadelain M. 2002 Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor Nat. Biotechnol. 20 70 75 10.1038/nbt0102-70 11753365
Majzner R. G. Theruvath J. L. Nellan A. Heitzeneder S. Cui Y. Mount C. W. Rietberg S. P. Linde M. H. Xu P. Rota C. Sotillo E. Labanieh L. Lee D. W. Orentas R. J. Dimitrov D. S. Zhu Z. Croix B. S. Delaidelli A. Sekunova A. Bonvini E. Mitra S. S. Quezado M. M. Majeti R. Monje M. Sorensen P. H. B. Maris J. M. Mackall C. L. 2019 CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors Clin. Cancer Res. 25 2560 2574 10.1158/1078-0432.CCR-18-0432 30655315
Malik-Chaudhry H. K. Prabhakar K. Ugamraj H. S. Boudreau A. A. Buelow B. Dang K. Davison L. M. Harris K. E. Jorgensen B. Ogana H. Pham D. Schellenberger U. Van Schooten W. Buelow R. Iyer S. Trinklein N. D. Rangaswamy U. S. 2021 TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL mAbs 13 1890411 10.1080/19420862.2021.1890411 33818299
Mangsbo S. M. Sandin L. C. Anger K. Korman A. J. Loskog A. Totterman T. H. 2010 Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy J. Immunother. 33 225 235 10.1097/CJI.0b013e3181c01fcb 20445343
Mhawech-Fauceglia P. Zhang S. Terracciano L. Sauter G. Chadhuri A. Herrmann F. R. Penetrante R. 2007 Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutipletumour tissue microarray technique Histopathology 50 472 483 10.1111/j.1365-2559.2007.02635.x 17448023
Miyoshi Y. Ando A. Egawa C. Taguchi T. Tamaki Y. Tamaki H. Sugiyama H. Noguchi S. 2002 High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients Clin. Cancer Res. 8 1167 1171 12006533
Motzer R. J. Tannir N. M. McDermott D. F. Aren Frontera O. Melichar B. Choueiri T. K. Plimack E. R. Barthelemy P. Porta C. George S. Powles T. Donskov F. Neiman V. Kollmannsberger C. K. Salman P. Gurney H. Hawkins R. Ravaud A. Grimm M. O. Bracarda S. Barrios C. H. Tomita Y. Castellano D. Rini B. I. Chen A. C. Mekan S. McHenry M. B. Wind-Rotolo M. Doan J. Sharma P. Hammers H. J. Escudier B. CheckMate 214 Investigators 2018 Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma N. Engl. J. Med. 378 1277 1290 10.1056/NEJMoa1712126 29562145
Mullard A. 2021 FDA approves first BCMA-targeted CAR-T cell therapy Nat. Rev. Drug Discov. 20 332 10.1038/d41573-021-00063-1 33790473
Nair-Gupta P. Diem M. Reeves D. Wang W. Schulingkamp R. Sproesser K. Mattson B. Heidrich B. Mendonca M. Joseph J. Sendecki J. Foulk B. Chu G. Fink D. Jiao Q. Wu S. J. Packman K. Elsayed Y. Attar R. Gaudet F. 2020 A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia Blood Adv. 4 906 919 10.1182/bloodadvances.2019001188 32150609
Neelapu S. S. Tummala S. Kebriaei P. Wierda W. Locke F. L. Lin Y. Jain N. Daver N. Gulbis A. M. Adkins S. Rezvani K. Hwu P. Shpall E. J. 2018 Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' Nat. Rev. Clin. Oncol. 15 218 10.1038/nrclinonc.2018.20 29434334
Ott P. A. Hu Z. Keskin D. B. Shukla S. A. Sun J. Bozym D. J. Zhang W. Luoma A. Giobbie-Hurder A. Peter L. Chen C. Olive O. Carter T. A. Li S. Lieb D. J. Eisenhaure T. Gjini E. Stevens J. Lane W. J. Javeri I. Nellaiappan K. Salazar A. M. Daley H. Seaman M. Buchbinder E. I. Yoon C. H. Harden M. Lennon N. Gabriel S. Rodig S. J. Barouch D. H. Aster J. C. Getz G. Wucherpfennig K. Neuberg D. Ritz J. Lander E. S. Fritsch E. F. Hacohen N. Wu C. J. 2017 An immunogenic personal neoantigen vaccine for patients with melanoma Nature 547 217 221 10.1038/nature22991 28678778
Palmer D. C. Guittard G. C. Franco Z. Crompton J. G. Eil R. L. Patel S. J. Ji Y. Van Panhuys N. Klebanoff C. A. Sukumar M. Clever D. Chichura A. Roychoudhuri R. Varma R. Wang E. Gattinoni L. Marincola F. M. Balagopalan L. Samelson L. E. Restifo N. P. 2015 Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance J. Exp. Med. 212 2095 2113 10.1084/jem.20150304 26527801
Porter D. L. Kalos M. Zheng Z. Levine B. June C. 2011a Chimeric antigen receptor therapy for B-cell malignancies J. Cancer 2 331 332 10.7150/jca.2.331 21716851
Porter D. L. Levine B. L. Kalos M. Bagg A. June C. H. 2011b Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl J. Med. 365 725 733 10.1056/NEJMoa1103849 21830940
Ramachandran I. Lowther D. E. Dryer-Minnerly R. Wang R. Fayngerts S. Nunez D. Betts G. Bath N. Tipping A. J. Melchiori L. Navenot J. M. Glod J. Mackall C. L. D'Angelo S. P. Araujo D. M. Chow W. A. Demetri G. D. Druta M. Van Tine B. A. Grupp S. A. Abdul Razak A. R. Wilky B. Iyengar M. Trivedi T. Winkle E. V. Chagin K. Amado R. Binder G. K. Basu S. 2019 Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma J. Immunother. Cancer 7 276 10.1186/s40425-019-0762-2 31651363
Rapoport A. P. Stadtmauer E. A. Binder-Scholl G. K. Goloubeva O. Vogl D. T. Lacey S. F. Badros A. Z. Garfall A. Weiss B. Finklestein J. Kulikovskaya I. Sinha S. K. Kronsberg S. Gupta M. Bond S. Melchiori L. Brewer J. E. Bennett A. D. Gerry A. B. Pumphrey N. J. Williams D. Tayton-Martin H. K. Ribeiro L. Holdich T. Yanovich S. Hardy N. Yared J. Kerr N. Philip S. Westphal S. Siegel D. L. Levine B. L. Jakobsen B. K. Kalos M. June C. H. 2015 NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Nat. Med. 21 914 921 10.1038/nm.3910 26193344
Reck M. Rodriguez-Abreu D. Robinson A. G. Hui R. Csoszi T. Fulop A. Gottfried M. Peled N. Tafreshi A. Cuffe S. O'Brien M. Rao S. Hotta K. Leiby M. A. Lubiniecki G. M. Shentu Y. Rangwala R. Brahmer J. R. KEYNOTE-024 Investigators 2016 Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N. Engl. J. Med. 375 1823 1833 10.1056/NEJMoa1606774 27718847
Riley R. S. June C. H. Langer R. Mitchell M. J. 2019 Delivery technologies for cancer immunotherapy Nat. Rev. Drug Discov. 18 175 196 10.1038/s41573-018-0006-z 30622344
Robbins P. F. Kassim S. H. Tran T. L. Crystal J. S. Morgan R. A. Feldman S. A. Yang J. C. Dudley M. E. Wunderlich J. R. Sherry R. M. Kammula U. S. Hughes M. S. Restifo N. P. Raffeld M. Lee C. C. Li Y. F. El-Gamil M. Rosenberg S. A. 2015 A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response Clin. Cancer Res. 21 1019 1027 10.1158/1078-0432.CCR-14-2708 25538264
Rosenberg S. A. Packard B. S. Aebersold P. M. Solomon D. Topalian S. L. Toy S. T. Simon P. Lotze M. T. Yang J. C. Seipp C. A. 1988 Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N. Engl. J. Med. 319 1676 1680 10.1056/NEJM198812223192527 3264384
Rosenberg S. A. Yang J. C. Sherry R. M. Kammula U. S. Hughes M. S. Phan G. Q. Citrin D. E. Restifo N. P. Robbins P. F. Wunderlich J. R. Morton K. E. Laurencot C. M. Steinberg S. M. White D. E. Dudley M. E. 2011 Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin. Cancer Res. 17 4550 4557 10.1158/1078-0432.CCR-11-0116 21498393
Rosenthal M. A. Balana C. van Linde M. E. Sayehli C. Fiedler W. M. Wermke M. Massard C. Mellinghoff I. K. Khasraw M. Ang A. Rasmussen E. Kast J. Stienen S. Cloughesy T. F. 2019 ATIM-49 (LTBK-01). AMG 596, a novel anti-EGFRvIII bispecific T cell engager (BITE(®)) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (RGBM) Neuro-Oncol 21 vi283 10.1093/neuonc/noz219.1195
Sahin U. Derhovanessian E. Miller M. Kloke B. P. Simon P. Lower M. Bukur V. Tadmor A. D. Luxemburger U. Schrors B. Omokoko T. Vormehr M. Albrecht C. Paruzynski A. Kuhn A. N. Buck J. Heesch S. Schreeb K. H. Muller F. Ortseifer I. Vogler I. Godehardt E. Attig S. Rae R. Breitkreuz A. Tolliver C. Suchan M. Martic G. Hohberger A. Sorn P. Diekmann J. Ciesla J. Waksmann O. Brück A. K. Witt M. Zillgen M. Rothermel A. Kasemann B. Langer D. Bolte S. Diken M. Kreiter S. Nemecek R. Gebhardt C. Grabbe S. Höller C. Utikal J. Huber C. Loquai C. Tureci O. 2017 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Nature 547 222 226 10.1038/nature23003 28678784
Schadendorf D. Hodi F. S. Robert C. Weber J. S. Margolin K. Hamid O. Patt D. Chen T. T. Berman D. M. Wolchok J. D. 2015 Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J. Clin. Oncol. 33 1889 1894 10.1200/JCO.2014.56.2736 25667295
Schlothauer T. Herter S. Koller C. F. Grau-Richards S. Steinhart V. Spick C. Kubbies M. Klein C. Umana P. Mossner E. 2016 Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions Protein Eng. Des. Sel. 29 457 466 10.1093/protein/gzw040 27578889
Schultz-Thater E. Piscuoglio S. Iezzi G. Le Magnen C. Zajac P. Carafa V. Terracciano L. Tornillo L. Spagnoli G. C. 2011 MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies Int. J. Cancer 129 1137 1148 10.1002/ijc.25777 21710496
Shimabukuro-Vornhagen A. Godel P. Subklewe M. Stemmler H. J. Schlosser H. A. Schlaak M. Kochanek M. Boll B. von Bergwelt-Baildon M. S. 2018 Cytokine release syndrome J. Immunother. Cancer 6 56 10.1186/s40425-018-0343-9 29907163
Song S. Han M. Zhang H. Wang Y. Jiang H. 2013 Full screening and accurate subtyping of HLA-A*02 alleles through group-specific amplification and mono-allelic sequencing Cell. Mol. Immunol. 10 490 496 10.1038/cmi.2013.33 23954948
Stein A. S. Schiller G. Benjamin R. Jia C. Zhang A. Zhu M. Zimmerman Z. Topp M. S. 2019 Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors Ann. Hematol. 98 159 167 10.1007/s00277-018-3497-0 30238148
Strome S. E. Dong H. Tamura H. Voss S. G. Flies D. B. Tamada K. Salomao D. Cheville J. Hirano F. Lin W. Kasperbauer J. L. Ballman K. V. Chen L. 2003 B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res. 63 6501 6505 14559843
Sugita Y. Wada H. Fujita S. Nakata T. Sato S. Noguchi Y. Jungbluth A. A. Yamaguchi M. Chen Y. T. Stockert E. Gnjatic S. Williamson B. Scanlan M. J. Ono T. Sakita I. Yasui M. Miyoshi Y. Tamaki Y. Matsuura N. Noguchi S. Old L. J. Nakayama E. Monden M. 2004 NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors Cancer Res. 64 2199 2204 10.1158/0008-5472.CAN-03-3070 15026363
Tan M. P. Gerry A. B. Brewer J. E. Melchiori L. Bridgeman J. S. Bennett A. D. Pumphrey N. J. Jakobsen B. K. Price D. A. Ladell K. Sewell A. K. 2015 T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells Clin. Exp. Immunol. 180 255 270 10.1111/cei.12570 25496365
Thakur A. Huang M. Lum L. G. 2018 Bispecific antibody based therapeutics: strengths and challenges Blood Rev. 32 339 347 10.1016/j.blre.2018.02.004 29482895
Topp M. S. Duell J. Zugmaier G. Attal M. Moreau P. Langer C. Kronke J. Facon T. Salnikov A. V. Lesley R. Beutner K. Kalabus J. Rasmussen E. Riemann K. Minella A. C. Munzert G. Einsele H. 2020 Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma J. Clin. Oncol. 38 775 783 10.1200/JCO.19.02657 31895611
Turley S. J. Cremasco V. Astarita J. L. 2015 Immunological hallmarks of stromal cells in the tumour microenvironment Nat. Rev. Immunol. 15 669 682 10.1038/nri3902 26471778
Twyman-Saint Victor C. Rech A. J. Maity A. Rengan R. Pauken K. E. Stelekati E. Benci J. L. Xu B. Dada H. Odorizzi P. M. Herati R. S. Mansfield K. D. Patsch D. Amaravadi R. K. Schuchter L. M. Ishwaran H. Mick R. Pryma D. A. Xu X. Feldman M. D. Gangadhar T. C. Hahn S. M. Wherry E. J. Vonderheide R. H. Minn A. J. 2015 Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 373 377 10.1038/nature14292 25754329
Viardot A. Goebeler M. E. Hess G. Neumann S. Pfreundschuh M. Adrian N. Zettl F. Libicher M. Sayehli C. Stieglmaier J. Zhang A. Nagorsen D. Bargou R. C. 2016 Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma Blood 127 1410 1416 10.1182/blood-2015-06-651380 26755709
Wang T. T. Ravetch J. V. 2019 Functional diversification of IgGs through Fc glycosylation J. Clin. Invest. 129 3492 3498 10.1172/JCI130029 31478910
Weber J. Mandala M. Del Vecchio M. Gogas H. J. Arance A. M. Cowey C. L. Dalle S. Schenker M. Chiarion-Sileni V. Marquez-Rodas I. Grob J. J. Butler M. O. Middleton M. R. Maio M. Atkinson V. Queirolo P. Gonzalez R. Kudchadkar R. R. Smylie M. Meyer N. Mortier L. Atkins M. B. Long G. V. Bhatia S. Lebbé C. Rutkowski P. Yokota K. Yamazaki N. Kim T. M. de Pril V. Sabater J. Qureshi A. Larkin J. Ascierto P. A. CheckMate 238 Collaborators 2017 Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma N. Engl. J. Med. 377 1824 1835 10.1056/NEJMoa1709030 28891423
Wilkie S. Burbridge S. E. Chiapero-Stanke L. Pereira A. C. Cleary S. van der Stegen S. J. Spicer J. F. Davies D. M. Maher J. 2010 Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4 J. Biol. Chem. 285 25538 25544 10.1074/jbc.M110.127951 20562098
Wing K. Onishi Y. Prieto-Martin P. Yamaguchi T. Miyara M. Fehervari Z. Nomura T. Sakaguchi S. 2008 CTLA-4 control over Foxp3+ regulatory T cell function Science 322 271 275 10.1126/science.1160062 18845758
Wolchok J. D. Chiarion-Sileni V. Gonzalez R. Rutkowski P. Grob J. J. Cowey C. L. Lao C. D. Wagstaff J. Schadendorf D. Ferrucci P. F. Smylie M. Dummer R. Hill A. Hogg D. Haanen J. Carlino M. S. Bechter O. Maio M. Marquez-Rodas I. Guidoboni M. McArthur G. Lebbé C. Ascierto P. A. Long G. V. Cebon J. Sosman J. Postow M. A. Callahan M. K. Walker D. Rollin L. Bhore R. Hodi F. S. Larkin J. 2017 Overall survival with combined nivolumab and ipilimumab in advanced melanoma N. Engl. J. Med. 377 1345 1356 10.1056/NEJMoa1709684 28889792
Wu J. Fu J. Zhang M. Liu D. 2015 Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia J. Hematol. Oncol. 8 104 10.1186/s13045-015-0195-4 26337639
Yang Y. F. Zou J. P. Mu J. Wijesuriya R. Ono S. Walunas T. Bluestone J. Fujiwara H. Hamaoka T. 1997 Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages Cancer Res. 57 4036 4041 9307290
Zacharakis N. Chinnasamy H. Black M. Xu H. Lu Y. C. Zheng Z. Pasetto A. Langhan M. Shelton T. Prickett T. Gartner J. Jia L. Trebska-McGowan K. Somerville R. P. Robbins P. F. Rosenberg S. A. Goff S. L. Feldman S. A. 2018 Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer Nat. Med. 24 724 730 10.1038/s41591-018-0040-8 29867227
Zehn D. Lee S. Y. Bevan M. J. 2009 Complete but curtailed T-cell response to very low-affinity antigen Nature 458 211 214 10.1038/nature07657 19182777
Zhang Y. Du X. Liu M. Tang F. Zhang P. Ai C. Fields J. K. Sundberg E. J. Latinovic O. S. Devenport M. Zheng P. Liu Y. 2019 Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy Cell Res. 29 609 627 10.1038/s41422-019-0184-1 31267017
Zhao J. Zhao J. Perlman S. 2012 Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-gamma, IL-2 and IL-2R PLoS ONE 7 e46241 10.1371/journal.pone.0046241 23029447
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.